signs Collaboration Agreement

signs Collaboration Agreement

will combine their proprietary technologies with the goal of

enhancement of growth and functionality of stem cells

Aviv, Israel - July 5, 2018 - Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production

technology, announced that it has signed a collaboration and material transfer agreement with the denovoMATRIX group of the Technische

Universit t Dresden (TU Dresden).

Dresden and its Center for Regenerative Therapies Dresden (CRTD), is one of the leading centers for stem cell research in Germany.

two entities believe that the combination of both proprietary technologies may result in significant enhancement of the overall

stem cell selection and expansion processes.

to the agreement, the team of denovoMATRIX employed by TU Dresden will conduct examinations into the tentative synergy between

Cellect's ApoGraft and the denovoMAtrix technology for the purpose of evaluating collaborative development of products

for regenerative medicine. To that end, a denovoMATRIX scientist will conduct a line of experiments in Cellect's R&D

the event of successful completion of the evaluation stage, both sides agreed to negotiate in good faith a potential mutual development

agreement, for the development of a stem cell related product. Cellect will have the sole discretion on determining the level

of success of the evaluation stage.

Cellect Biotechnology Ltd.

Biotechnology (NASDAQ: APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue that

aims to improve a variety of stem cell-based therapies.

Company's technology is expected to provide research, hospitals and pharma companies with the tools to rapidly isolate stem

cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative

medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking

statements can be identified by the use of forward-looking words such as "believe", "expect", "intend",

"plan", "may", "should", "could", "might", "seek", "target",

"will", "project", "forecast", "continue" or "anticipate" or their

negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to

historical matters. For example, forward-looking statements are used in this press release when we discuss the Company's

belief regarding the results of any future collaboration with denovoMATRIX. These forward-looking statements and their implications

are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties

that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical

results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar

conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise.

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking

statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to

obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties

of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's

ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its

methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials;

the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability

to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able

to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual

property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties

may develop with the Company's technology; and the Company's ability to retain or attract key employees whose knowledge

is essential to the development of its products.. Any forward-looking statement in this press release speaks only as of the date

of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether

as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors"

in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2017 filed with the U.S. Securities and Exchange

Commission ("SEC"), which is available on the SEC's website, www.sec.gov, and in the Company's periodic

filings with the SEC.

Leibovitz, Chief Financial Officer